Our researchers have found a way to dramatically slow neuroblastoma growth, using a combination of drugs that starves cells of essential nutrients called polyamines.
Research Assistant Olivia Ciampa recently spent six months working in a collaborator’s lab at the Mayo Clinic, Minnesota, USA. I asked her why she went there, what it was like, and what she achieved.
Groundbreaking research from our Leukaemia Biology Program has revealed how acute lymphoblastic leukaemia can become resistant to a class of anti-cancer drugs called glucocorticoids.
Our researchers have developed a method to measure the amount of copper inside neuroblastoma tumours. Published in the journal Theranostics, it offers a potential tool for treating and monitoring neuroblastoma.
Twenty-six police officers and one cancer researcher took to the skies last Sunday to raise funds for childhood cancer research. The inaugural Great Cop Drop was inspired by Isla, a little girl diagnosed with leukaemia four years ago.
A drug called OBI-3424 has been designated an Orphan Drug by the U.S. Food and Drug Administration (FDA) to treat acute lymphoblastic leukaemia, based predominantly on research carried out by our Leukaemia Biology Program.
Olivia Lambert was a bright and happy little girl with an infectious smile and a fun-loving spirit. Diagnosed with stage 4 neuroblastoma at age two and a half, she fought the disease bravely for six years. Her legacy and spirit continue with the appointment of Dr Joshua McCarroll as the Olivia Lambert Team Leader.
This week we’re looking at Drug Discovery – the development of new cancer treatments. Because it’s only with more effective, less toxic cancer drugs that we’ll be able to save the life of every child with cancer and improve their long-term health.
The 9th International Nanomedicine Conference was held last week in Coogee, Sydney. Some of our researchers were there, showcasing their research and networking with colleagues from near and far.
Our scientists have been forging alliances in China that will open the door to research collaborations and speed the progress of childhood cancer research.